Analysts downgraded revenue forecasts for Akoya Biosciences (NASDAQ:AKYA) signaling a weaker outlook. Revenue estimates were cut sharply, with a 14% projected sales growth in 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Analysts downgraded revenue forecasts for Akoya Biosciences (NASDAQ:AKYA) signaling a weaker outlook. Revenue estimates were cut sharply, with a 14% projected sales growth in 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.